title: Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.
abstract: Considerable progress has been achieved over the past 15 years in uncovering the biological basis of major psychiatric disorders. To determine patterns of brain dysfunction and to uncover the mechanism of action of centrally active compounds we used single photon emission computerized tomography (SPECT) as well as positron emission tomography (PET) in patients diagnosed with schizophrenia, depression, bulimia and Tourette's disorder. Striatal D2 and 5-HT1A receptors were studied in schizophrenia and 5-HT transporters (5-HTT) in depression and bulimia. Patients were either drug-naïve or drug free, or we studied the influence of specifically acting compounds on receptor/transporter occupancy. We could demonstrate that atypical antipsychotics have a dose-dependent (with the exception of clozapine and quetiapine) lower striatal D2 receptor occupancy rate compared with typical neuroleptics, paralleling the more favourable extrapyramidal side effects of atypical antipsychotics. However, no association between striatal D2 receptor occupancy rates and antipsychotic efficacy has been found. The measurement of 5-HT1A receptors in drug-naïve schizophrenic patients using the in vivo PET methodology revealed an increase of cortical 5-HT1A receptor binding potential in schizophrenia. beta-CIT as a ligand for measurement of 5-HT transporter densities (5-HTT) revealed lower rates in depression compared to age- and sex-matching healthy controls, a measurement that has also been obtained for bulimia. We also documented seasonal variations in brain serotonergic function by our finding of reduced brain 5-HTT availability in winter (compared to summer) in healthy controls. Furthermore, displaceable [123I] beta-CIT binding in the area corresponding to the left striatum (representing predominantly the density of dopamine transporters) was significantly reduced in SAD patients compared to healthy controls. In depression as well as in bulimia, selective serotonin reuptake inhibitors significantly decreased the beta-CIT binding potential, however, no significant dose relationship has been obtained in depression. Genotyping depressed patients for the serotonin transporter promoter gene region (5-HTTLPR) did not provide evidence for in vivo functional regulation of 5-HTT availability by 5-HTTLPR in the thalamus-hypothalamus and mesencephalon-pons of healthy subjects. In patients suffering from Tourette's disorder (TD) we were unable to detect differences of dopamine transporter densities between psychotropic drug-naïve TD patients and controls. Furthermore, no difference could be found between currently treated (with antipsychotics) and psychotropic drug-naïve TD patients. Our data provide insight into the pathophysiology of neuropsychiatric disorders and may guide future psychopharmacological drug developments.
authors.affiliation: Department of General Psychiatry, University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. SK@akh-wien.ac.at
authors.forename: Siegfried
authors.initials: S
authors.lastname: Kasper
authors.forename: Johannes
authors.initials: J
authors.lastname: Tauscher
authors.forename: Matthäus
authors.initials: M
authors.lastname: Willeit
authors.forename: Mara
authors.initials: M
authors.lastname: Stamenkovic
authors.forename: Alexander
authors.initials: A
authors.lastname: Neumeister
authors.forename: Bernd
authors.initials: B
authors.lastname: Küfferle
authors.forename: Christian
authors.initials: C
authors.lastname: Barnas
authors.forename: Jürgen
authors.initials: J
authors.lastname: Stastny
authors.forename: Nicole
authors.initials: N
authors.lastname: Praschak-Rieder
authors.forename: Lukas
authors.initials: L
authors.lastname: Pezawas
authors.forename: Martina
authors.initials: M
authors.lastname: de Zwaan
authors.forename: Sylvia
authors.initials: S
authors.lastname: Quiner
authors.forename: Walter
authors.initials: W
authors.lastname: Pirker
authors.forename: Susanne
authors.initials: S
authors.lastname: Asenbaum
authors.forename: Ivo
authors.initials: I
authors.lastname: Podreka
authors.forename: Thomas
authors.initials: T
authors.lastname: Brücke
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism*; D002032:Bulimia / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D050483:Dopamine Plasma Membrane Transport Proteins; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism*; D026901:Membrane Transport Proteins / Q000378:metabolism*; D009419:Nerve Tissue Proteins; D011401:Promoter Regions, Genetic / Q000235:genetics; D011954:Receptors, Dopamine / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism*; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics; D012621:Seasons; D050486:Serotonin Plasma Membrane Transport Proteins; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon; D005879:Tourette Syndrome / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D002352:Carrier Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins